Article de revue
Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programm
Australia implemented conjugate meningococcal C immunization in
2003 with a single scheduled dose at age 12 months and catch-up for
individuals aged 2–19 years. Several countries have recently added
one or more booster doses to their programmes to maintain disease
control. Australian disease surveillance and vaccine coverage data
were used to assess longer term vaccine coverage and impact on
invasive serogroup C disease incidence and mortality, and review
vaccine failures. Coverage was 93% in 1-year-olds and 70% for
catch-up cohorts. In 10 years, after adjusting for changes in
diagnostic practices, population invasive serogroup C incidence
declined 96% (95% confidence interval 94–98) to 0·4 and 0·6
cases/million in vaccinated and unvaccinated cohorts, respectively.
Only three serogroup C deaths occurred in 2010–2012 vs. 68 in
2000–2002. Four (<1/million doses) confirmed vaccine failures
were identified in 10 years with no increasing trend. Despite
published evidence of waning antibody over time, an ongoing single
dose of meningococcal C conjugate vaccine in the second year of
life following widespread catch-up has resulted in near elimination
of serogroup C disease in all age groups without evidence of
vaccine failures in the first decade since introduction.
Concurrently, serogroup B incidence declined independently by
55%.
Auteurs
Langues
- Anglais
Année de publication
2016
Journal
Epidemiology and Infection
Volume
11
Type
Article de revue
Catégories
- Prestation de services
Maladies
- Méningite à méningocoques
Pays
- Australie
Mots-clés
- Suivi de la couverture
- Suivi de performance
- Politique et législation
Régions de l'OMS
- Région du Pacifique occidental
